A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes

A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2... Adv Ther (2017) 34:1791–1814 DOI 10.1007/s12325-017-0499-6 REVIEW A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes . . Stefano Genovese Edoardo Mannucci Antonio Ceriello Received: March 22, 2016 / Published online: July 3, 2017 The Author(s) 2017. This article is an open access publication insulin glargine, as measured by HbA1c. In ABSTRACT drug-naı¨ve patients ExeOW was superior to sitagliptin and non-inferior to metformin, Introduction: Exenatide once weekly (ExeOW, whereas non-inferiority to pioglitazone and Bydureon , Astra Zeneca), a drug belonging to liraglutide was not proven. In different trials the class of glucagon-like peptide-1 (GLP-1) reductions in HbA1c ranged from -1.1% to receptor agonists, is the first agent approved for -2.0%. ExeOW therapy over 6 months was also treatment of type 2 diabetes (T2D) that can be associated with a mean weight loss of -2to administered on a weekly basis. -4 kg, improved systolic blood pressure and Methods: Data concerning treatment of T2D lipid profile, and no hypoglycemia unless asso- with ExeOW are reviewed with special reference ciated to sulfonylurea. ExeOW long-term ther- to its long-term efficacy, tolerability, and safety. apy up to 3–6 years allowed persistent glycemic Relevant literature was identified http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Therapy Springer Journals

A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes

Loading next page...
 
/lp/springer_journal/a-review-of-the-long-term-efficacy-tolerability-and-safety-of-BT2vtF2KLT
Publisher
Springer Healthcare
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology
ISSN
0741-238X
eISSN
1865-8652
D.O.I.
10.1007/s12325-017-0499-6
Publisher site
See Article on Publisher Site

Abstract

Adv Ther (2017) 34:1791–1814 DOI 10.1007/s12325-017-0499-6 REVIEW A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes . . Stefano Genovese Edoardo Mannucci Antonio Ceriello Received: March 22, 2016 / Published online: July 3, 2017 The Author(s) 2017. This article is an open access publication insulin glargine, as measured by HbA1c. In ABSTRACT drug-naı¨ve patients ExeOW was superior to sitagliptin and non-inferior to metformin, Introduction: Exenatide once weekly (ExeOW, whereas non-inferiority to pioglitazone and Bydureon , Astra Zeneca), a drug belonging to liraglutide was not proven. In different trials the class of glucagon-like peptide-1 (GLP-1) reductions in HbA1c ranged from -1.1% to receptor agonists, is the first agent approved for -2.0%. ExeOW therapy over 6 months was also treatment of type 2 diabetes (T2D) that can be associated with a mean weight loss of -2to administered on a weekly basis. -4 kg, improved systolic blood pressure and Methods: Data concerning treatment of T2D lipid profile, and no hypoglycemia unless asso- with ExeOW are reviewed with special reference ciated to sulfonylurea. ExeOW long-term ther- to its long-term efficacy, tolerability, and safety. apy up to 3–6 years allowed persistent glycemic Relevant literature was identified

Journal

Advances in TherapySpringer Journals

Published: Jul 3, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off